| Risperdal Consta (risperidone depot formulation) / J&J |
NCT00246246: A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder |
|
|
| Completed | 3 | 48 | US | risperidone | Janssen-Ortho Inc., Canada | Bipolar Disorder | | 04/06 | | |
NCT00094926: A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes. |
|
|
| Completed | 3 | 275 | US | Risperdal Consta, placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Bipolar Disorder | | 02/07 | | |
| Completed | 3 | 559 | US, Europe, RoW | Risperdal Consta, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | 10/07 | 12/07 | | |
| Completed | 3 | 50 | US | Injectable Risperidone (Consta) or oral antipsychotic, Long actiing risperidone injection (Consta), oral risperidone (risperdal)., Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify) | University of Pittsburgh, Janssen Pharmaceuticals | Bipolar I Disorder | 03/08 | 12/09 | | |
NCT00391222: A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder |
|
|
| Completed | 3 | 585 | Europe, RoW | Olanzapine, Placebo, Risperidone Long Acting Injectable (LAI) | Janssen Pharmaceutica N.V., Belgium | Bipolar Disorder | 04/09 | 04/09 | | |
